BidaskClub Upgrades Alexion Pharmaceuticals (ALXN) to Buy

Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

Several other research analysts have also weighed in on the company. Cowen reissued a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday. Guggenheim assumed coverage on Alexion Pharmaceuticals in a research report on Friday, February 22nd. They set a “neutral” rating and a $135.00 price target on the stock. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Morgan Stanley upped their price target on Alexion Pharmaceuticals from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Tuesday, February 12th. Finally, Credit Suisse Group reissued a “buy” rating and set a $156.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, January 22nd. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $160.73.

NASDAQ:ALXN opened at $136.09 on Friday. The firm has a market cap of $30.41 billion, a P/E ratio of 19.19, a price-to-earnings-growth ratio of 1.00 and a beta of 1.55. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $140.77. The company has a current ratio of 2.88, a quick ratio of 2.48 and a debt-to-equity ratio of 0.31.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.54. The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. Alexion Pharmaceuticals’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.48 earnings per share. Equities research analysts predict that Alexion Pharmaceuticals will post 8.51 EPS for the current year.

In other Alexion Pharmaceuticals news, CAO Daniel Bazarko sold 2,000 shares of the business’s stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $126.00, for a total value of $252,000.00. Following the transaction, the chief accounting officer now owns 5,020 shares in the company, valued at $632,520. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ludwig Hantson sold 3,244 shares of the business’s stock in a transaction dated Monday, December 31st. The shares were sold at an average price of $95.85, for a total value of $310,937.40. Following the completion of the transaction, the chief executive officer now owns 150,696 shares in the company, valued at approximately $14,444,211.60. The disclosure for this sale can be found here. Insiders sold 8,488 shares of company stock worth $873,875 in the last 90 days. Corporate insiders own 4.35% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ALXN. FMR LLC boosted its stake in shares of Alexion Pharmaceuticals by 25.1% during the 4th quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock worth $2,570,135,000 after acquiring an additional 5,301,272 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Alexion Pharmaceuticals by 0.3% during the 3rd quarter. BlackRock Inc. now owns 16,302,528 shares of the biopharmaceutical company’s stock worth $2,266,214,000 after acquiring an additional 41,943 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Alexion Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after acquiring an additional 192,857 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Alexion Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after acquiring an additional 192,857 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Alexion Pharmaceuticals by 1.2% during the 4th quarter. Jennison Associates LLC now owns 8,728,912 shares of the biopharmaceutical company’s stock worth $849,847,000 after acquiring an additional 101,376 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: What is the Gross Domestic Product (GDP)?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.